Using DAOs to Develop Medicine and Pharmaceutical Products
summary
Claims a DAO-funded model that repurposes existing drugs using a proprietary yeast‑based platform that gives a functional code to genes and compounds, screening 3,000+ compounds in-house and matching against 7,500 approved medicines and 21,000 human genes. Reports finding 7 drugs for COVID within hours, one drug showing a ~60% retrospective mortality reduction and another rescuing mortality in a blinded trial, and plans a fair auction token launch with Uniswap liquidity to finance development while keeping IP and regulatory approvals with the biotech company.
AI-written summary · about
chapters (11)
- 0:00Pharma DAOs introduction
- 2:08Pharma DAOs governance
- 7:03Traditional pharma limits
- 12:46The unique advantages of decentralized pharmaceutical innovation
- 20:26Pharma DAO challenges
- 24:17Data ownership in DAOs
- 27:06Personalized medicine via DAOs
- 28:51Q&A on DAO accountability
- 33:09IP ownership in DAOs
- 36:43DAO tokenomics
- 41:56Closing remarks